Neuren Pharmaceuticals Annual Report 2020

Neuren Pharmaceuticals is developing new therapies for debilitating neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells. Incorporated in New Zealand and based in Melbourne, Australia, Neuren is listed on the ASX under the code NEU. 1 Neuren’s value proposition 2 Chairman and CEO message 3 Operating Review 18 Management Team 20 Board 21 Corporate Governance 28 Directors’ Report 32 Consolidated Statement of Comprehensive Income 33 Consolidated Statement of Financial Position 34 Consolidated Statement of Changes in equity 35 Consolidated Statement of Cash Flows 36 Notes to the Consolidated Financial Statements 50 Independent Auditor’s Report 53 Additional Information Contents